Share
Feel brighter every day with our 20-minute pop-biz news podcast. The 3 business stories you need, with fresh takes you can pretend you came up with — Pairs perfectly with your morning oatmeal ritual. Hosted by Jack Crivici-Kramer & Nick Martell. Formerly known as “Snacks Daily”, Nick and Jack continue their podcast independent from Robinhood.
…
continue reading
Manage episode 519428704 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this week’s episode of "The Top Line," we take a deep dive into the top-line performance of the biopharma industry in the third quarter.
After a slow start to the year, U.S. drugmakers in particular have recovered, led by Eli Lilly. We examine which companies are hot and which are not. We also look at trends that emerged in the third quarter, such as the shortfall in vaccine sales, especially in the U.S., and companies’ sales projections for the rest of the year.
Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss their observations from the third quarter and put the industry’s performance in perspective compared with previous quarters. They also examine the biopharma outlook for the fourth quarter.
To learn more about the topics in this episode:
- Q1 biopharma layoff trends, plus expectations for Q2
- 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms
- Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year
See omnystudio.com/listener for privacy information.
100 episodes
))
